Ethnicity and coronary artery disease: the role of high-density lipoprotein – a change in paradigm

References

• Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation 2015;131(4):e29-e322
   PubMed Web of Science ®Google Scholar
• Avendano M, Kawachi I. Why do Americans have shorter life expectancy and worse health than do people in other high-income countries? Annu Rev Public Health 2014;35:307-25
   PubMed Web of Science ®Google Scholar
• Healthy People 2020. Foundation Health Measures. Disparities. Available from: http://healthypeople.gov/2020/about/DisparitiesAbout.aspx
   Google Scholar
• Clark LT, Lingegowda U. Acute coronary syndromes in black Americans: is treatment different? Should it be? Curr Cardiol Rep 2005;7(4):249-54
   PubMedGoogle Scholar
• DeVon HA, Burke LA, Nelson H, et al. Disparities in patients presenting to the emergency department with potential acute coronary syndrome: it matters if you are Black or White. Heart Lung 2014;43(4):270-7
   Google Scholar
• Eastwood JA, Johnson BD, Rutledge T, et al. Anginal symptoms, coronary artery disease, and adverse outcomes in Black and White women: the NHLBI-sponsored Women’s Ischemia Syndrome Evaluation (WISE) study. J Womens Health (Larchmt) 2013;22(9):724-32
   Web of Science ®Google Scholar
• Cohen MG, Fonarow GC, Peterson ED, et al. Racial and ethnic differences in the treatment of acute myocardial infarction: findings from the Get With the Guidelines-Coronary Artery Disease program. Circulation 2010;121(21):2294-301
   Google Scholar
• King-Shier KM, Singh S, Leblanc P, et al. The influence of ethnicity and gender on navigating an acute coronary syndrome event. Eur J Cardiovasc Nurs 2014;14(3):240-7
   Google Scholar
• Freund KM, Jacobs AK, Pechacek JA, et al. Disparities by race, ethnicity, and sex in treating acute coronary syndromes. J Womens Health (Larchmt) 2012;21(2):126-32
   Google Scholar
• Weintraub WS, Vaccarino V. Explaining racial disparities in coronary outcomes in women. Circulation 2003;108(9):1041-3
   Google Scholar
• Vaccarino V, Rathore SS, Wenger NK, et al. Sex and racial differences in the management of acute myocardial infarction. 1994 through 2002. N Engl J Med 2005;353(7):671-82
   Google Scholar
• Singh JA, Lu X, Ibrahim S, et al. Trends in and disparities for acute myocardial infarction: an analysis of Medicare claims data from 1992 to 2010. BMC Med 2014;12(1):190
   PubMedGoogle Scholar
• Cavender MA, Rassi AN, Fonarow GC, et al. Relationship of race/ethnicity with door-to-balloon time and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: findings from Get With the Guidelines-Coronary Artery Disease. Clin Cardiol 2013;36(12):749-56
   Google Scholar
• Gupta A, Wang Y, Spertus JA, et al. Trends in acute myocardial infarction in young patients and differences by sex and race, 2001 to 2010. J Am Coll Cardiol 2014;64(4):337-45
   PubMed Web of Science ®Google Scholar
• Booth JNIII, Levitan EB, Brown TM, et al. Effect of sustaining lifestyle modifications (nonsmoking, weight reduction, physical activity, and Mediterranean diet) after healing of myocardial infarction, percutaneous intervention, or coronary bypass (from the REasons for Geographic and Racial Differences in Stroke Study). Am J Cardiol 2014;113(12):1933-40
   Google Scholar
• Shaw LJ, Butler J. Targeting priority populations to reduce disparities in cardiovascular care: health equity for all. J Am Coll Cardiol 2014;64(4):346-8
   Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(25 Suppl 2):S1-45
   PubMed Web of Science ®Google Scholar
• Luscher TF, Landmesser U, von Eckardstein A, et al. High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target. Circ Res 2014;114(1):171-82
   PubMedGoogle Scholar
• Rosenson RS, Brewer HBJr, Ansell B, et al. Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges. Circulation 2013;128(11):1256-67
   Google Scholar
• Rader DJ, Hovingh GK. HDL and cardiovascular disease. Lancet 2014;384(9943):618-25
   PubMed Web of Science ®Google Scholar
• Tan Y, Liu TR, Hu SW, et al. Acute coronary syndrome remodels the protein cargo and functions of high-density lipoprotein subfractions. PLoS One 2014;9(4):e94264
   PubMed Web of Science ®Google Scholar
• Tian L, Li C, Liu Y, et al. The value and distribution of high-density lipoprotein subclass in patients with acute coronary syndrome. PLoS One 2014;9(1):e85114
   PubMed Web of Science ®Google Scholar
• Toth PP, Barter PJ, Rosenson RS, et al. High-density lipoproteins: a consensus statement from the National Lipid Association. J Clin Lipidol 2013;7(5):484-525
   PubMed Web of Science ®Google Scholar
• Yancey PG, Bortnick AE, Kellner-Weibel G, et al. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 2003;23(5):712-19
   PubMed Web of Science ®Google Scholar
• Bounafaa A, Berrougui H, Ikhlef S, et al. Alteration of HDL functionality and PON1 activities in acute coronary syndrome patients. Clin Biochem 2014;47(18):318-25
   PubMed Web of Science ®Google Scholar
• Goff DCJr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(25 Suppl 2):S49-73
   PubMed Web of Science ®Google Scholar
• Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79(1):8-15
   PubMed Web of Science ®Google Scholar
• Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 1988;8(6):737-41
   PubMedGoogle Scholar
• Corti MC, Guralnik JM, Salive ME, et al. HDL cholesterol predicts coronary heart disease mortality in older persons. JAMA 1995;274(7):539-44
   Google Scholar
• Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001;104(10):1108-13
   PubMed Web of Science ®Google Scholar
• Huxley RR, Barzi F, Lam TH, et al. Isolated low levels of high-density lipoprotein cholesterol are associated with an increased risk of coronary heart disease: an individual participant data meta-analysis of 23 studies in the Asia-Pacific region. Circulation 2011;124(19):2056-64
   PubMed Web of Science ®Google Scholar
• Muntner P, Lee F, Astor BC. Association of high-density lipoprotein cholesterol with coronary heart disease risk across categories of low-density lipoprotein cholesterol: the atherosclerosis risk in communities study. Am J Med Sci 2011;341(3):173-80
   Google Scholar
• Guo ZG, Li C, Zhong JK, et al. Laboratory investigation of dysfunctional HDL. Chem Phys Lipids 2012;165(1):32-7
   Google Scholar
• Lee ET, Welty TK, Fabsitz R, et al. The Strong Heart Study. A study of cardiovascular disease in American Indians: design and methods. Am J Epidemiol 1990;132(6):1141-55
   PubMed Web of Science ®Google Scholar
• Zambon A, Deeb SS, Hokanson JE, et al. Common variants in the promoter of the hepatic lipase gene are associated with lower levels of hepatic lipase activity, buoyant LDL, and higher HDL2 cholesterol. Arterioscler Thromb Vasc Biol 1998;18(11):1723-9
   Google Scholar
• Group HTC. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013;34(17):1279-91
   PubMed Web of Science ®Google Scholar
• Investigators AH, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365(24):2255-67
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341(6):410-18
   PubMed Web of Science ®Google Scholar
• Frank AT, Zhao B, Jose PO, et al. Racial/ethnic differences in dyslipidemia patterns. Circulation 2014;129(5):570-9
   PubMed Web of Science ®Google Scholar
• Rodriguez CJ, Daviglus ML, Swett K, et al. Dyslipidemia patterns among Hispanics/Latinos of diverse background in the United States. Am J Med 2014;127(12):1186-94 e1
   PubMed Web of Science ®Google Scholar
• Dodani S. Coronary artery diseases in South Asian immigrants: an update on high density lipoprotein role in disease prevention. J Immigr Minor Health 2009;11(5):415-21
   Google Scholar
• Rubins HB, Robins SJ, Collins D, et al. Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group. Am J Cardiol 1995;75(17):1196-201
   PubMed Web of Science ®Google Scholar
• Li C, Ford ES, Meng YX, et al. Does the association of the triglyceride to high-density lipoprotein cholesterol ratio with fasting serum insulin differ by race/ethnicity? Cardiovasc Diabetol 2008;7:4
   PubMed Web of Science ®Google Scholar
• D’Agostino RBSr, Grundy S, Sullivan LM, et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001;286(2):180-7
   PubMed Web of Science ®Google Scholar
• Woodard GA, Brooks MM, Barinas-Mitchell E, et al. Lipids, menopause, and early atherosclerosis in Study of Women’s Health Across the Nation Heart women. Menopause 2011;18(4):376-84
   Google Scholar
• Bots ML, Elwood PC, Nikitin Y, et al. Total and HDL cholesterol and risk of stroke. EUROSTROKE: a collaborative study among research centres in Europe. J Epidemiol Community Health 2002;56(Suppl 1):i19-24
   Google Scholar
• Wilkins JT, Ning H, Stone NJ, et al. Coronary heart disease risks associated with high levels of HDL cholesterol. J Am Heart Assoc 2014;3(2):e000519
   PubMed Web of Science ®Google Scholar
• Oldoni F, Sinke RJ, Kuivenhoven JA. Mendelian disorders of high-density lipoprotein metabolism. Circ Res 2014;114(1):124-42
   Google Scholar
• Hovingh GK, de Groot E, van der Steeg W, et al. Inherited disorders of HDL metabolism and atherosclerosis. Curr Opin Lipidol 2005;16(2):139-45
   Google Scholar
• Dean BB, Borenstein JE, Henning JM, et al. Can change in high-density lipoprotein cholesterol levels reduce cardiovascular risk? Am Heart J 2004;147(6):966-76
   Google Scholar
• Ashen MD, Blumenthal RS. Clinical practice. Low HDL cholesterol levels. N Engl J Med 2005;353(12):1252-60
   Web of Science ®Google Scholar
• Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357(21):2109-22
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367(22):2089-99
   PubMed Web of Science ®Google Scholar
• Barter P. Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Am J Cardiol 2009;104(10 Suppl):10E-5E
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Tardif JC, Schwartz GG, et al. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. JAMA 2014;311(15):1515-25
   PubMed Web of Science ®Google Scholar
• Hage MP, Azar ST. Treating low high-density lipoprotein cholesterol: what is the evidence? Ther Adv Endocrinol Metab 2014;5(1):10-17
   Google Scholar
• Hafiane A, Jabor B, Ruel I, et al. High-density lipoprotein mediated cellular cholesterol efflux in acute coronary syndromes. Am J Cardiol 2014;113(2):249-55
   Google Scholar
• Onat A, Hergenc G. Low-grade inflammation, and dysfunction of high-density lipoprotein and its apolipoproteins as a major driver of cardiometabolic risk. Metabolism 2011;60(4):499-512
   Google Scholar
• Krychtiuk KA, Kastl SP, Pfaffenberger S, et al. Small high-density lipoprotein is associated with monocyte subsets in stable coronary artery disease. Atherosclerosis 2014;237(2):589-96
   Google Scholar
• Sini S, Deepa D, Harikrishnan S, et al. Evidence for an exclusive association of matrix metalloproteinase-9 with dysfunctional high-density lipoprotein: a novel finding. Atherosclerosis 2014;236(1):162-8
   Google Scholar
• Rohatgi A, Khera A, Berry JD, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med 2014;371(25):2383-93
   PubMed Web of Science ®Google Scholar
• Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011;364(2):127-35
   PubMed Web of Science ®Google Scholar
• Turner S, Voogt J, Davidson M, et al. Measurement of reverse cholesterol transport pathways in humans: in vivo rates of free cholesterol efflux, esterification, and excretion. J Am Heart Assoc 2012;1(4):e001826
   Google Scholar
• Cuchel M, Rader DJ. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation 2006;113(21):2548-55
   PubMed Web of Science ®Google Scholar
• Victor RG, Haley RW, Willett DL, et al. The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. Am J Cardiol 2004;93(12):1473-80
   PubMed Web of Science ®Google Scholar
• Chandra A, Neeland IJ, Das SR, et al. Relation of black race between high density lipoprotein cholesterol content, high density lipoprotein particles and coronary events (from the Dallas Heart Study). Am J Cardiol 2015;115(7):890-4
   Google Scholar
• Mackey RH, Greenland P, Goff DCJr, et al. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J Am Coll Cardiol 2012;60(6):508-16
   PubMed Web of Science ®Google Scholar
• Tang WH, Hartiala J, Fan Y, et al. Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk. Arterioscler Thromb Vasc Biol 2012;32(11):2803-12
   PubMed Web of Science ®Google Scholar
• Huang Y, Wu Z, Riwanto M, et al. Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. J Clin Invest 2013;123(9):3815-28
   PubMed Web of Science ®Google Scholar
• Gugliucci A. Activation of paraoxonase 1 is associated with HDL remodeling ex vivo. Clin Chim Acta 2014;429:38-45
   PubMed Web of Science ®Google Scholar
• Graner M, James RW, Kahri J, et al. Association of paraoxonase-1 activity and concentration with angiographic severity and extent of coronary artery disease. J Am Coll Cardiol 2006;47(12):2429-35
   PubMed Web of Science ®Google Scholar
• Gugliucci A, Menini T. Paraoxonase 1 and HDL maturation. Clin Chim Acta 2015;439:5-13
   PubMed Web of Science ®Google Scholar
• Akinkuolie AO, Paynter NP, Padmanabhan L, et al. High-density lipoprotein particle subclass heterogeneity and incident coronary heart disease. Circ Cardiovasc Qual Outcomes 2014;7(1):55-63
   Google Scholar
• Dodani S, Dong L, Guirgis FW, et al. Carotid intima media thickness and low high-density lipoprotein (HDL) in South Asian immigrants: could dysfunctional HDL be the missing link? Arch Med Sci 2014;10(5):870-9
   Google Scholar
• Gugliucci A, Caccavello R, Nassar H, et al. Low protective PON1 lactonase activity in an Arab population with high rates of coronary heart disease and diabetes. Clin Chim Acta 2015;445:41-7
   Google Scholar
• Barylski M, Toth PP, Nikolic D, et al. Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality. Best Pract Res Clin Endocrinol Metab 2014;28(3):453-61
   PubMed Web of Science ®Google Scholar
• Tardif JC, Gregoire J, L’Allier PL, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007;297(15):1675-82
   PubMed Web of Science ®Google Scholar
• Waksman R, Torguson R, Kent KM, et al. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol 2010;55(24):2727-35
   PubMed Web of Science ®Google Scholar
• Kuhnast S, van der Tuin SJ, van der Hoorn JW, et al. Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin. Eur Heart J 2015;36(1):39-48
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Brewer HB, Kastelein JJ, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 2011;306(19):2099-109
   PubMed Web of Science ®Google Scholar
• Havel RJ. Introduction: John Gofman and the early years at the Donner Laboratory. J Clin Lipidol 2007;1(2):100-3
   Google Scholar
• Stein EA, Giugliano RP, Koren MJ, et al. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Eur Heart J 2014;35(33):2249-59
   PubMed Web of Science ®Google Scholar
• Robinson JG, Nedergaard BS, Rogers WJ, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA 2014;311(18):1870-82
   PubMed Web of Science ®Google Scholar
• National Institutes of Health, National Heart, Lung, and Blood Institute. Hispanic Community Health Study/Study of Latinos Data Book: A Report to the Communities. NIH Publication No. 13-7951 Department of Health and Human Services; Bethesda, MD, US: 2013
   Google Scholar
• Rader DJ. Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 2006;116(12):3090-100
   PubMed Web of Science ®Google Scholar